Ergothioneine
A molecule with its own transporter, a compelling aging story, and almost no human trials.
D+
Evidence grade
D
Worth it
$25-45/month
Typical cost
DoseStudies use 5 to 25 mg/day of L-ergothioneine; European novel-food approval covers up to 30 mg/day for adults. Mushroom intake (especially porcini, oyster, and shiitake) provides roughly 1 to 5 mg in a generous serving, so supplements deliver several-fold dietary exposure, a fact that cuts in both directions: it is food-derived, and the doses are not food-level.
BasisErgothioneine may be the most interesting molecule in this tier and it still grades D+.
Ergothioneine is a sulfur-containing amino acid made by fungi and some bacteria, obtained by humans almost entirely from mushrooms. We grade Ergothioneine D+ on evidence and D for worth-it at about $25-45 per month.
What it does
Ergothioneine is a sulfur-containing amino acid made by fungi and some bacteria, obtained by humans almost entirely from mushrooms. It accumulates in the body via a dedicated transporter and is marketed as a longevity antioxidant, riding cohort data and a famous hypothesis (the 'longevity vitamin' argument) rather than trial results.
What the research says
The transporter argument: your body has dedicated machinery to keep this molecule
Evidence: emerging. Ergothioneine is the rare dietary compound with its own specific membrane transporter (OCTN1), discovered in 2005, which concentrates it in tissues exposed to oxidative stress. Blood levels fall with age, and lower levels track with cognitive impairment and frailty in cohort studies. All of that is biology and association; none of it is a trial result, and the supplement industry routinely presents the first as if it were the second.
Human efficacy trials barely exist yet
Evidence: weak. The clinical file is pilot-scale: safety and pharmacokinetic studies confirming it is well tolerated and retained, one small Japanese trial reporting improved sleep-quality measures, and small cognition studies in older adults now appearing. No trial has tested a disease outcome, a functional endpoint at scale, or duration beyond months. Anyone stating what ergothioneine does for human health is extrapolating from cohorts and rodents.
Ergothioneine may be the most interesting molecule in this tier and it still grades D+. The reasons to watch it are real: a dedicated human transporter, tissue concentration where oxidative damage happens, and cohort levels that track with healthy aging. The reasons it cannot grade higher are equally real: essentially no human efficacy trials. This library grades evidence, not promise, and the record is written to be the page that ages well whichever way the first real trials land.
Is it worth it?
Evidence (D+) sits far below the leaderboard floor, so the worth-it grade is capped at C+ however it is priced; the derived value lands at D, because this is an expensive molecule with no human efficacy data yet. About $35 a month at studied doses. Derived from the October 2026 worth-it model.
Typical cost
$25-45/month
Common form, not a brand recommendation
Dosage context established
Studies use 5 to 25 mg/day of L-ergothioneine; European novel-food approval covers up to 30 mg/day for adults. Mushroom intake (especially porcini, oyster, and shiitake) provides roughly 1 to 5 mg in a generous serving, so supplements deliver several-fold dietary exposure, a fact that cuts in both directions: it is food-derived, and the doses are not food-level.
Worth-it leaderboard
Ergothioneine sits outside the worth-it top 20.
Ergothioneine sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Nothing concerning so far: long dietary history via mushrooms, clean safety studies at supplement doses, and European novel-food approval. Absence of long-term supplement-dose data is the only caveat, and it applies to the entire category of new longevity molecules. No interactions are documented.
Longevity Lab Report
Ergothioneine news. Graded when it happens.
The grade on this page stays free. The email carries the news on ergothioneine: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from the transporter and cohort literature and the pilot trial file. The record separates what is genuinely interesting about this molecule (a dedicated transporter is a real scientific signal) from what is not yet known (any human health effect), because the marketing merges them.
- 2026-10-23|Not listed under any goal: no graded human benefit exists yet to map.
The week's longevity and biohacking news.
This grade for Ergothioneine rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.